Literature DB >> 18807011

Serum levels of osteopontin are increased in SIRS and sepsis.

Rosanna Vaschetto1, Stefania Nicola, Carlo Olivieri, Elena Boggio, Fabio Piccolella, Riccardo Mesturini, Federica Damnotti, Davide Colombo, Paolo Navalesi, Francesco Della Corte, Umberto Dianzani, Annalisa Chiocchetti.   

Abstract

OBJECTIVE: In sepsis, dysregulation of the immune response leads to rapid multiorgan failure and death. Accurate and timely diagnosis is lifesaving and should discriminate sepsis from the systemic inflammatory response syndrome (SIRS) caused by non-infectious agents. Osteopontin acts as an extracellular matrix component or a soluble cytokine in inflamed tissues. Its exact role in immune response and sepsis remains to be elucidated. Therefore, we investigated the role of osteopontin in SIRS and sepsis.
DESIGN: Prospective, observational study.
SETTING: Intensive care unit of a university hospital. PATIENTS AND PARTICIPANTS: Fifty-six patients with SIRS or sepsis and 56 healthy subjects were enrolled.
INTERVENTIONS: We analyzed the serum levels of osteopontin and TH1-TH2 cytokines and investigated the role of osteopontin on interleukin 6 secretion by monocytes.
MEASUREMENTS AND MAIN RESULTS: Serum osteopontin levels were strikingly higher in patients than in controls and in sepsis than in SIRS, and decreased during the resolution of both the disorders. Receiver operating characteristic curves showed that osteopontin levels have discriminative power between SIRS and sepsis with an area under the curve of 0.796. Osteopontin levels directly correlated with those of interleukin 6 and in vitro, recombinant osteopontin increased interleukin 6 secretion by monocytes in both the absence and presence of high doses of lipopolysaccharide.
CONCLUSION: These data suggest that osteopontin might be a mediator involved in the pathogenesis of SIRS and sepsis, possibly by supporting interleukin 6 secretion. DESCRIPTOR: 45. SIRS/Sepsis: clinical studies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18807011     DOI: 10.1007/s00134-008-1268-4

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  40 in total

Review 1.  Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis.

Authors:  Benjamin M P Tang; Guy D Eslick; Jonathan C Craig; Anthony S McLean
Journal:  Lancet Infect Dis       Date:  2007-03       Impact factor: 25.071

2.  High plasma osteopontin levels in patients with inflammatory bowel disease.

Authors:  Ryosuke Mishima; Fuminao Takeshima; Terumitsu Sawai; Kazuo Ohba; Ken Ohnita; Hajime Isomoto; Katsuhisa Omagari; Yohei Mizuta; Yoshiyuki Ozono; Shigeru Kohno
Journal:  J Clin Gastroenterol       Date:  2007-02       Impact factor: 3.062

3.  Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis.

Authors:  S Harbarth; K Holeckova; C Froidevaux; D Pittet; B Ricou; G E Grau; L Vadas; J Pugin
Journal:  Am J Respir Crit Care Med       Date:  2001-08-01       Impact factor: 21.405

4.  Osteopontin is strongly expressed by alveolar macrophages in the lungs of acute respiratory distress syndrome.

Authors:  Fumiyuki Takahashi; Kazuhisa Takahashi; Kazue Shimizu; Ri Cui; Norihiro Tada; Hideki Takahashi; Sanae Soma; Masakata Yoshioka; Yoshinosuke Fukuchi
Journal:  Lung       Date:  2004       Impact factor: 2.584

5.  Plasma osteopontin levels in multiple sclerosis.

Authors:  Manuel Comabella; Imma Pericot; Robert Goertsches; Carlos Nos; Mireia Castillo; José Blas Navarro; Jordi Río; Xavier Montalban
Journal:  J Neuroimmunol       Date:  2005-01       Impact factor: 3.478

6.  Progression of diabetic nephropathy enhances the plasma osteopontin level in type 2 diabetic patients.

Authors:  Hiroshi Yamaguchi; Masahiko Igarashi; Akihiko Hirata; Hiromi Tsuchiya; Kazuhiko Sugiyama; Yoshihiro Morita; Yumi Jimbu; Hiroshi Ohnuma; Makoto Daimon; Makoto Tominaga; Takeo Kato
Journal:  Endocr J       Date:  2004-10       Impact factor: 2.349

7.  Procalcitonin: a marker to clearly differentiate systemic inflammatory response syndrome and sepsis in the critically ill patient?

Authors:  Evangelos J Giamarellos-Bourboulis; Anna Mega; Paraskevi Grecka; Nektaria Scarpa; George Koratzanis; George Thomopoulos; Helen Giamarellou
Journal:  Intensive Care Med       Date:  2002-08-07       Impact factor: 17.440

8.  Reduced postischemic macrophage infiltration and interstitial fibrosis in osteopontin knockout mice.

Authors:  Veerle P Persy; Anja Verhulst; Dirk K Ysebaert; Kathleen E De Greef; Marc E De Broe
Journal:  Kidney Int       Date:  2003-02       Impact factor: 10.612

9.  A nuclear factor for IL-6 expression (NF-IL6) is a member of a C/EBP family.

Authors:  S Akira; H Isshiki; T Sugita; O Tanabe; S Kinoshita; Y Nishio; T Nakajima; T Hirano; T Kishimoto
Journal:  EMBO J       Date:  1990-06       Impact factor: 11.598

10.  Osteopontin gene haplotypes correlate with multiple sclerosis development and progression.

Authors:  Annalisa Chiocchetti; Cristoforo Comi; Manuela Indelicato; Luca Castelli; Riccardo Mesturini; Thea Bensi; Maria C Mazzarino; Mara Giordano; Sandra D'Alfonso; Patricia Momigliano-Richiardi; Maria Liguori; Marino Zorzon; Antonio Amoroso; Maria Trojano; Francesco Monaco; Maurizio Leone; Corrado Magnani; Umberto Dianzani
Journal:  J Neuroimmunol       Date:  2005-04-25       Impact factor: 3.478

View more
  29 in total

1.  Osteopontin in sepsis: any role?

Authors:  Marc Derive; Sébastien Gibot
Journal:  Intensive Care Med       Date:  2008-09-20       Impact factor: 17.440

Review 2.  Biomarkers for the differentiation of sepsis and SIRS: the need for the standardisation of diagnostic studies.

Authors:  T C Hall; D K Bilku; D Al-Leswas; C Horst; A R Dennison
Journal:  Ir J Med Sci       Date:  2011-07-30       Impact factor: 1.568

3.  Osteopontin is associated with inflammation and mortality in a mouse model of polymicrobial sepsis.

Authors:  S Fortis; R G Khadaroo; J J Haitsma; H Zhang
Journal:  Acta Anaesthesiol Scand       Date:  2014-10-19       Impact factor: 2.105

Review 4.  Sepsis biomarkers: a review.

Authors:  Charalampos Pierrakos; Jean-Louis Vincent
Journal:  Crit Care       Date:  2010-02-09       Impact factor: 9.097

5.  Osteopontin impairs host defense during established gram-negative sepsis caused by Burkholderia pseudomallei (melioidosis).

Authors:  Gerritje J W van der Windt; W Joost Wiersinga; Catharina W Wieland; Ivo C S I Tjia; Nicholas P Day; Sharon J Peacock; Sandrine Florquin; Tom van der Poll
Journal:  PLoS Negl Trop Dis       Date:  2010-08-31

6.  Neutralization of Osteopontin Ameliorates Acute Lung Injury Induced by Intestinal Ischemia-Reperfusion.

Authors:  Yohei Hirano; Monowar Aziz; Weng-Lang Yang; Mahendar Ochani; Ping Wang
Journal:  Shock       Date:  2016-10       Impact factor: 3.454

Review 7.  Current trends in inflammatory and immunomodulatory mediators in sepsis.

Authors:  Monowar Aziz; Asha Jacob; Weng-Lang Yang; Akihisa Matsuda; Ping Wang
Journal:  J Leukoc Biol       Date:  2012-11-07       Impact factor: 4.962

8.  Early Blood Biomarkers Distinguish Inflammation from Neonatal Hypoxic-Ischemia Encephalopathy.

Authors:  Po-Ming Wu; Chih-Hao Lin; Hsueh-Te Lee; Hsin-I Shih; Chao-Ching Huang; Yi-Fang Tu
Journal:  Neurochem Res       Date:  2020-09-08       Impact factor: 3.996

9.  Novel Biomarkers for Diagnosing Periprosthetic Joint Infection from Synovial Fluid and Serum.

Authors:  Hannes Keemu; Felix Vaura; Anu Maksimow; Mikael Maksimow; Aleksi Jokela; Maija Hollmén; Keijo Mäkelä
Journal:  JB JS Open Access       Date:  2021-04-20

Review 10.  Mechanisms of intermittent hypoxia induced hypertension.

Authors:  Laura V González Bosc; Thomas Resta; Benjimen Walker; Nancy L Kanagy
Journal:  J Cell Mol Med       Date:  2009-10-10       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.